Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of momelotinib plus luspatercept in transfusion-dependent myelofibrosis
2024-518225-15-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Apr 2025
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib and luspatercept in myelofibrosis (MF), sponsored by GSK. Primary endpoint: Transfusion independence by end of Week 24. Planned start Apr 2025; status: authorised.
02
Drugs
mivavotinibluspatercept
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-518225-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518225-15-00.